Literature DB >> 11862176

Optimizing wound healing in the face after laser abrasion.

Mitchel P Goldman1, Thomas L Roberts, Greg Skover, John T Lettieri, Richard E Fitzpatrick.   

Abstract

BACKGROUND: Laser resurfacing is a popular procedure to improve the physical signs of photoaging. In addition to improvements in treatment modalities, optimizing posttreatment regimens will enhance patient care.
OBJECTIVE: Our purpose was to evaluate the efficacy of two forms of wound care for the face after laser abrasion.
METHODS: Forty-two patients received full-face laser resurfacing at two clinics by using either the UltraPulse carbon dioxide (CO(2)) laser (Coherent Laser Corp, Palo Alto, Calif) alone or followed by an erbium:YAG laser (Derma-20, ESC Sharplan, Inc, Needham, Mass) and/or a blended CO(2)/Er:YAG laser (Derma-K, ESC Sharplan) or a variable pulse erbium:YAG laser (Contour, Sciton Laser Corp, Palo Alto). Twenty-one patients were randomly assigned to a postoperative regimen including Silon-TSR (Bio Med Sciences, Inc, Allentown, Pa) for the first 2 to 3 days after laser resurfacing, followed by Aquaphor ointment (Beiersdorf, Charlotte, NC) to complete the first 2 weeks. The other 21 patients received the resurfacing recovery system (RRS, Neutrogena, Los Angeles, Calif) following a specific regimen. The system includes Fibracol wound dressing (Johnson & Johnson, Skillman, NJ) for 2 days, followed by a hydrogel dressing for 1 to 2 days, followed by an ointment to complete the first 2 weeks. Patients were evaluated for wound healing on days 2, 3, 6-10, 14-16, and 28-30. The skin was swabbed for colonization at every visit to determine the quantity of bacteria throughout the healing process.
RESULTS: Ninety percent of patients in both groups experienced either "no pain" or "minimal pain" during the first 3 days. Total bacterial counts peaked on days 3 and 6 in the patients managed with the RRS and the Silon-TSR/Aquaphor regimen, respectively. The average day at which patients did not require a dressing was 3.0 days in the group managed with the RRS and 3.7 days in the group managed with the Silon-TSR/Aquaphor dressing regimen (P < or =.05). The average day of complete epithelial regeneration was significantly shorter at 6.3 days using the RRS compared with 7.4 days for patients using the Silon-TSR/Aquaphor regimen (P < or =.02). There was no difference in infection, adverse sequelae, exudate management, or pain in either group.
CONCLUSION: Healing was optimized in patients using the RRS after laser resurfacing.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11862176     DOI: 10.1067/mjd.2002.118358

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

Review 1.  [Laser treatment of wrinkles. Update].

Authors:  Claudia Borelli
Journal:  Hautarzt       Date:  2007-03       Impact factor: 0.751

2.  Improving the outcome of fractional CO2 laser resurfacing using a probiotic skin cream: Preliminary clinical evaluation.

Authors:  Giovanni Zoccali; Benedetta Cinque; Cristina La Torre; Francesca Lombardi; Paola Palumbo; Lucia Romano; Antonella Mattei; Gino Orsini; Maria Grazia Cifone; Maurizio Giuliani
Journal:  Lasers Med Sci       Date:  2016-07-13       Impact factor: 3.161

3.  Physical properties of hydrogel wound dressing and its use in low-level laser therapy (LLLT).

Authors:  K Wachal; E Stachowska; K Korpuścińska; B Nowak; Z Krasiński
Journal:  Lasers Med Sci       Date:  2018-04-02       Impact factor: 3.161

4.  Fractional carbon dioxide laser resurfacing.

Authors:  William M Ramsdell
Journal:  Semin Plast Surg       Date:  2012-08       Impact factor: 2.314

Review 5.  Review of Post-laser-resurfacing Topical Agents for Improved Healing and Cosmesis.

Authors:  Kunal Angra; Michael B Lipp; Sahil Sekhon; Douglas C Wu; Mitchel P Goldman
Journal:  J Clin Aesthet Dermatol       Date:  2021-08-01

6.  A Topical Anti-inflammatory Healing Regimen Utilizing Conjugated Linolenic Acid for Use Post-ablative Laser Resurfacing of the Face: A Randomized, Controlled Trial.

Authors:  Douglas C Wu; Mitchel P Goldman
Journal:  J Clin Aesthet Dermatol       Date:  2017-10-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.